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Cells in
oronary Artery Disease
ifferent Effects of
ifferent T-Cell Subsets*
ål Aukrust, MD, PHD,†‡ Arne Yndestad, PHD,†
iggo J. Sandberg, MSC,†
ars Gullestad, MD, PHD,§
an K. Damås, MD, PHD†‡
slo, Norway
he simplistic view of atherosclerosis as a disorder of
athologic lipid deposition has been redefined by the
ore complex concept of an ongoing inflammatory re-
ponse (1). Several cellular components seem to partici-
ate in this persistent inflammation, such as macro-
hages, vascular smooth muscle cells (VSMC), and
ndothelial cells. The presence of activated T cells in all
tages of atherogenesis implies that these cells also are
nvolved in the aggravation of atherosclerotic disorders
2). Indeed, T-cell– deficient severe combined immuno-
eficiency mice on an apolipoprotein E (apoE)-knockout
ackground develop less atherosclerotic disease than do
mmunocompetent apoE-knockout mice (3). On the
ther hand, transfer of CD4 T cells into these immunodefi-
ient atherosclerotic mice accelerates the disease (3).
See page 1450
It has been suggested that only subsets of T cells account
or their proatherogenic activity. Recently, Zhou et al. (3)
howed that the absence of CD4 cells in apoE/ mice
eads to reduced atherosclerosis, indicating that CD4 T
ells constitute a major proatherogenic cell population, and
here is solid evidence from several independent groups that
he T helper type 1 (TH1) subset is such a particular
roatherogenic subset. First, a number of studies have
olocalized CD4 T cells and interferon (IFN)- within
therosclerotic lesions, suggesting predominance of TH1
ells in atherogenesis (4). More recently, high levels of
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From the †Research Institute for Internal Medicine, ‡Section of Clinical Immu-s
ology and Infectious Diseases, and the §Department of Cardiology, Rikshospitalet-
adiumhospitalet Medical Center, University of Oslo, Oslo, Norway.nterleukin (IL)-12 and IL-18 have also been detected in
therosclerotic plaques, further suggesting a TH1 profile in
hese lesions (5). Second, a direct role in atherogenesis has
een defined in atherosclerotic-susceptible mice that are
eficient in either IFN- receptors or the cytokine itself (6).
onversely, injection of IFN- or the IFN-–releasing
actors IL-12 and 18 enhances the extent of disease in
poE/ mice (7). These findings may be due to the fact
hat IFN- activates endothelial cells and inhibits collagen
ynthesis in VSMC. This cytokine may also activate mac-
ophages to produce reactive oxygen species and matrix
etalloproteinases, suggesting a role for TH1-related cyto-
ines not only in atherogenesis, but also in plaque destabi-
ization (8). Finally, monocytes from patients with unstable
ngina exhibit a molecular fingerprint of a recent IFN-
riggering, and such patients also have raised plasma levels
f IL-18 that significantly correlated with the degree of
yocardial dysfunction, further implicating TH1-mediated
mmune responses in the pathogenesis of acute coronary
yndromes (ACS) (9).
H2 Cells: Friend or Foe?
number of experiments suggest that TH2-driven humoral
mmune responses may be atheroprotective. Thus, IL-5, a
ypical TH2 cytokine, was recently shown to attenuate
therosclerosis, in part by stimulating the expansion of
theroprotective natural immunoglobulin M specific for
xidized low-density lipoprotein (oxLDL) (1,2). Moreover,
switch toward a TH2 cytokine profile in mouse models of
therosclerosis has been found to be associated with
ncreased production of protective anti-oxLDL antibod-
es (1,2). Finally, production of high titers of immuno-
lobulin M-type anti-oxLDL antibodies, as in the case
ollowing immunization of LDLR/ mice with
alondialdehyde-LDL, is associated with reduced lesion
ize (10). Taken together, these studies suggest an
ttenuating effect of TH2 cells on atherogenesis, at least
artly involving the induction of atheroprotective anti-
odies. However, TH2 cytokines may also contribute to
he formation of aneurysms by inducing elastolytic en-
ymes, and switching the immune response of atheroscle-
osis from TH1 to TH2 may not necessarily attenuate
ascular disease. Thus, IL-4, the prototypic TH2 cyto-
ine, exhibits inflammatory (e.g., induction of chemo-
ines) and oxidative (activation of NADPH oxidase)
roperties and has been suggested to contribute to
ascular inflammation in disorders such as atherosclerosis
nd asthma. In fact, deficiency in IL-4 is associated with
decrease in atherosclerotic lesion formation, particularly
t the advanced stages of lesion progression (11).
egulatory T Cells:
otential Inhibitors of Atherogenesis
everal reports suggest antiatherogenic and plaque-
tabilizing effects of IL-10 involving anti-inflammatory,
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Editorial Comment October 9, 2007:1459–61atrix stabilizing, antithrombotic, and antiapoptotic effects
12). Also, transforming growth factor (TGF)-, another
-cell–derived antiinflammatory cytokine, has been shown
o possess potent antiatherogenic properties. Thus, when
poE-knockout mice were crossed with transgenic mice
arrying a dominant negative TGF- receptor II in T cells,
he offspring developed markedly increased atherosclerosis
ith larger and more unstable lesions (2). A specific
omponent of the immune system, known as the
D4CD25 regulatory T cells (Treg), is specialized for the
uppression of both TH1 and TH2 pathogenic immune
esponses against self or foreign antigens, and, interestingly,
his T-cell subset seems to be a major cellular source of
L-10 and TGF-, making it an attractive therapeutic
arget in preventing atherosclerosis. In fact, these T cells
ave been found to be powerful inhibitors of atherosclerosis
n mouse models (13). Moreover, Heller et al. recently
howed the expression of Treg within human atherosclerotic
esions, colocalized with both IL-10 and TGF-1 expres-
ion (14). These findings are consistent with a critical role of
hese immunosuppressive cytokines (i.e., IL-10 and
GF-) in Treg-mediated atheroprotection. Moreover, en-
agement of cytotoxic T-lymphocyte antigen 4 on Treg with
D80/CD86 on pathogenic cells has been identified as
ell–cell contact mechanisms of suppression, at least in
itro.
D4CD28 T Cells: Inflammatory
nd Proatherogenic T-Cell Subset
he CD4CD28 cells are a rare subset of long-lived
irectly cytotoxic CD4 T cells that secrete high levels of
FN-, and that have been implicated in the pathogenesis of
arious inflammatory disorders. In contrast to Treg, these T
ells possess proatherogenic and plaque-destabilizing prop-
rties. Thus, this T-cell subset has been found to preferen-
ially infiltrate unstable plaque and contribute to increased
ndothelial cell lysis in patients with ACS (15). Moreover,
D4CD28 T cells, isolated from either the plaque tissue
r the blood of patients with ACS, spontaneously express
L-12 receptors (16). In animal models, CD4CD28 T
ells respond to any IL-12–inducing host infection with a
hift in tissue trafficking and accrual in inflammatory le-
ions, such as an atherosclerotic lesion (16). In this issue of
he Journal, Liuzzo et al. (17) present novel data underscor-
ng the in vivo relevance of this inflammatory T-cell subset
or human coronary artery disease. This group has previ-
usly reported that patients with unstable angina, but not
hose with stable angina, experience expansion of the CD4
cells that lack the CD28 marker (18). They have also
hown accumulation of this T-cell subset in unstable coro-
ary plaques, suggesting that these cells may be involved in
laque instability (15). Here they extend these findings by
howing that the frequency of this aggressive and inflam-
atory T-cell phenotype in peripheral blood predicts recur-ent episodes of instability in patients with unstable angina.lthough they further underscore the potential pathogenic
ole of CD4CD28 T cells in immune-mediated plaque
estabilization, their novel findings also suggest that quan-
ification of this T-cell subset could be useful in the
election of patients at risk for future and recurrent coronary
vents. Based on the potential pathogenic role in plaque
estabilization, modulation of CD4CD28 T cells in
atients with unstable angina may be clinically relevant.
here are some reports suggesting that statins may down-
egulate this T-cell subset, further supporting a role for
tatins in the management of unstable disease (19). Inter-
stingly, the same team has also recently reported that the
xpansion of CD4CD28 T cells in patients with unstable
ngina may be reduced by selective TNF- blockade (i.e.,
nfliximab) (20). Although caution should be taken when using
uch therapy in unstable angina, because of the potential risk
or induction of apoptosis of TNF-expressing cells within the
nstable lesion (e.g., foam cells, endothelial cells, and VSMC),
heir finding illustrates the potential for immunomodulating
herapy in this disorder.
onclusions
lthough the pathogenic role of T cells in atherogenesis and
laque destabilization is well established, the complex func-
ion of the various T-cell subsets in this disorder is far from
lear. Although activation of Treg may be an interesting
ntiatherogenic target, activation of the inflammatory
D4CD28 T-cell subsets may promote plaque rupture
nd the development of ACS. However, the dynamics of
-cell response within the plaque are still poorly under-
tood, and both antigen-dependent (e.g., heat shock pro-
eins, oxidized lipoproteins, different microbial antigens)
nd antigen-independent (e.g., IL-7 and -15) stimuli may
e involved in the oligoclonal expansion of T cells in
therosclerotic plaques. Moreover, recent studies suggest
hat even other T-cell subsets than those that are discussed
ere may be involved in atherogenesis, such as the TH17
ubset, which produces the inflammatory cytokine IL-17,
nd CCR7 T cells, potentially playing a role in the
romotion of T-cell infiltration and inflammation within
he atherosclerotic lesion (2,21). Nevertheless, the different
ature of the various T-cell subsets as well as their complex
ole in atherogenesis and plaque destabilization underscores
hat future research in T-cell immunology not only is of
nterest to the basic research field but also may have
elevance to clinical cardiology.
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